KRSA CYCLERION THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, CYCLERION THERAPEUTICS INC reported revenue of n/a, net income of −$1.76M and diluted EPS of −$0.41; for the fiscal year ended December 2025 revenue was $2.07M, up 3.7% on the year before.

KRSA annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $2.07M, gross profit n/a, operating income −$4.97M, net income −$3.53M (margin -170.1%), EPS −$1.11
• Fiscal year ended Dec 2024: revenue $2.00M, gross profit n/a, operating income −$3.63M, net income −$3.06M (margin -152.9%), EPS −$1.21
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$13.0M, net income −$5.26M (margin n/a), EPS −$2.25
• Fiscal year ended Dec 2022: revenue $297K, gross profit n/a, operating income −$18.5M, net income −$44.1M (margin -14841.1%), EPS −$20.28
• Fiscal year ended Dec 2021: revenue $3.94M, gross profit n/a, operating income −$55.2M, net income −$51.6M (margin -1310.2%), EPS −$1.32

KRSA quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$1.76M, EPS −$0.41
• Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$3.18M, EPS −$0.76
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.03M (down 43.2% year over year), net income −$799K, EPS −$0.14
• Quarter ended Sep 30, 2025: revenue $875K (up 351.0% year over year), net income −$976K, EPS −$0.30
• Quarter ended Jun 30, 2025: revenue $93.0K, net income −$324K, EPS −$0.11
• Quarter ended Mar 31, 2025: revenue $81.0K, net income −$1.43M, EPS −$0.56
• Quarter ended Dec 31, 2024 (from the annual report): revenue $1.81M, net income $530K, EPS $0.23
• Quarter ended Sep 30, 2024: revenue $194K, net income −$723K, EPS −$0.29
• Quarter ended Jun 30, 2024: revenue $0, net income −$1.32M, EPS −$0.53
• Quarter ended Mar 31, 2024: revenue $0, net income −$1.54M, EPS −$0.62
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (up 100.0% year over year), net income −$1.69M, EPS $0.06
• Quarter ended Sep 30, 2023: revenue $0, net income $7.57M, EPS $2.72
• Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$4.18M, EPS −$1.83
• Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$6.95M, EPS −$3.20
• Quarter ended Dec 31, 2022 (from the annual report): revenue −$720K (down 235.3% year over year), net income −$7.22M, EPS −$8.99
• Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$10.5M, EPS −$4.83
• Quarter ended Jun 30, 2022: revenue $306K (down 89.8% year over year), net income −$13.4M, EPS −$6.16
• Quarter ended Mar 31, 2022: revenue $711K (up 1046.8% year over year), net income −$13.0M, EPS −$0.30
• Quarter ended Dec 31, 2021 (from the annual report): revenue $532K, net income −$17.2M, EPS −$0.22
• Quarter ended Sep 30, 2021: revenue $348K, net income −$11.3M, EPS −$0.26

KRSA cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$3.31M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$4.33M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$21.2M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$40.6M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$36.5M, share buybacks n/a

KRSA balance sheet

• Jun 30, 2026: cash $1.39M, total assets $6.93M, total liabilities n/a, shareholders' equity $5.09M
• Mar 31, 2026: cash $2.82M, total assets $8.51M, total liabilities n/a, shareholders' equity $6.79M
• Dec 31, 2025: cash $3.24M, total assets $9.99M, total liabilities n/a, shareholders' equity $9.09M
• Sep 30, 2025: cash $4.57M, total assets $10.4M, total liabilities n/a, shareholders' equity $9.54M
• Jun 30, 2025: cash $3.01M, total assets $9.37M, total liabilities n/a, shareholders' equity $8.57M
• Mar 31, 2025: cash $3.64M, total assets $9.85M, total liabilities n/a, shareholders' equity $8.78M
• Dec 31, 2024: cash $3.23M, total assets $9.58M, total liabilities n/a, shareholders' equity $8.85M
• Sep 30, 2024: cash $2.87M, total assets $8.90M, total liabilities n/a, shareholders' equity $8.20M

What is KRSA's revenue?

CYCLERION THERAPEUTICS INC reported $2.07M of revenue for the fiscal year ended December 2025.

Is KRSA profitable?

No. CYCLERION THERAPEUTICS INC lost $6.71M over the last four quarters.

What is KRSA's EPS?

Diluted earnings per share over the last four quarters were −$1.61; −$0.41 in the latest quarter.

KRSA ownership and insider trades · All stocks